company background image
4578

Otsuka HoldingsTSE:4578 Stock Report

Market Cap

JP¥2.2t

7D

-0.3%

1Y

-3.4%

Updated

30 Nov, 2021

Data

Company Financials +
4578 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends3/6

4578 Stock Overview

Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide.

Otsuka Holdings Competitors

Roche Holding

SWX:ROG

CHF310.8b

Sanofi

ENXTPA:SAN

€105.3b

Ajinomoto

TSE:2802

JP¥1.9t

Yakult HonshaLtd

TSE:2267

JP¥919.2b

Price History & Performance

Summary of all time highs, changes and price drops for Otsuka Holdings
Historical stock prices
Current Share PriceJP¥4,146.00
52 Week HighJP¥5,013.00
52 Week LowJP¥4,017.00
Beta0.51
1 Month Change-7.74%
3 Month Change-12.81%
1 Year Change-3.42%
3 Year Change-23.11%
5 Year Change-7.66%
Change since IPO93.74%

Recent News & Updates

Shareholder Returns

4578JP PharmaceuticalsJP Market
7D-0.3%-4.2%-4.6%
1Y-3.4%-10.2%8.9%

Return vs Industry: 4578 exceeded the JP Pharmaceuticals industry which returned -10.2% over the past year.

Return vs Market: 4578 underperformed the JP Market which returned 8.9% over the past year.

Price Volatility

Is 4578's price volatile compared to industry and market?
4578 volatility
4578 Average Weekly Movement2.7%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement4.0%
10% most volatile stocks in JP Market8.0%
10% least volatile stocks in JP Market2.2%

Stable Share Price: 4578 is less volatile than 75% of JP stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4578's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192133,151Tatsuo Higuchihttps://www.otsuka.com

Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine.

Otsuka Holdings Fundamentals Summary

How do Otsuka Holdings's earnings and revenue compare to its market cap?
4578 fundamental statistics
Market CapJP¥2.19t
Earnings (TTM)JP¥147.02b
Revenue (TTM)JP¥1.46t

0.0x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4578 income statement (TTM)
RevenueJP¥1.46t
Cost of RevenueJP¥469.91b
Gross ProfitJP¥993.38b
ExpensesJP¥846.36b
EarningsJP¥147.02b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin67.89%
Net Profit Margin10.05%
Debt/Equity Ratio7.0%

How did 4578 perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

18%

Payout Ratio

Does 4578 pay a reliable dividends?

See 4578 dividend history and benchmarks
When do you need to buy 4578 by to receive an upcoming dividend?
Otsuka Holdings dividend dates
Ex Dividend DateDec 29 2021
Dividend Pay DateMar 31 2022
Days until Ex dividend28 days
Days until Dividend pay date120 days

Does 4578 pay a reliable dividends?

See 4578 dividend history and benchmarks

Valuation

Is Otsuka Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 4578 (¥4146) is trading below our estimate of fair value (¥8641.41)

Significantly Below Fair Value: 4578 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: Insufficient data to calculate 4578's PE Ratio to determine if it is good value compared to the JP Pharmaceuticals industry average.

PE vs Market: Insufficient data to calculate 4578's PE Ratio to determine if it is good value compared to the JP market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4578's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: Insufficient data to calculate 4578's PB Ratio to determine if it is good value.


Future Growth

How is Otsuka Holdings forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

2.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4578's forecast earnings growth (2% per year) is above the savings rate (0.02%).

Earnings vs Market: 4578's earnings (2% per year) are forecast to grow slower than the JP market (10.3% per year).

High Growth Earnings: 4578's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4578's revenue (1.9% per year) is forecast to grow slower than the JP market (4.9% per year).

High Growth Revenue: 4578's revenue (1.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4578's Return on Equity is forecast to be low in 3 years time (8.1%).


Past Performance

How has Otsuka Holdings performed over the past 5 years?

13.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4578 has high quality earnings.

Growing Profit Margin: 4578's current net profit margins (10%) are higher than last year (10%).


Past Earnings Growth Analysis

Earnings Trend: 4578's earnings have grown by 13% per year over the past 5 years.

Accelerating Growth: 4578's earnings growth over the past year (2.5%) is below its 5-year average (13% per year).

Earnings vs Industry: 4578 earnings growth over the past year (2.5%) underperformed the Pharmaceuticals industry 9.3%.


Return on Equity

High ROE: 4578's Return on Equity (7.5%) is considered low.


Financial Health

How is Otsuka Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 4578's short term assets (¥1,064.1B) exceed its short term liabilities (¥484.6B).

Long Term Liabilities: 4578's short term assets (¥1,064.1B) exceed its long term liabilities (¥313.5B).


Debt to Equity History and Analysis

Debt Level: 4578 has more cash than its total debt.

Reducing Debt: 4578's debt to equity ratio has reduced from 16.9% to 7% over the past 5 years.

Debt Coverage: 4578's debt is well covered by operating cash flow (140%).

Interest Coverage: 4578 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Otsuka Holdings's current dividend yield, its reliability and sustainability?

2.41%

Current Dividend Yield


Upcoming Dividend Payment

TodayNov 30 2021Ex Dividend DateDec 29 2021Dividend Pay DateMar 31 202292 days from Ex DividendBuy in the next 28 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4578's dividend (2.41%) is higher than the bottom 25% of dividend payers in the JP market (1.41%).

High Dividend: 4578's dividend (2.41%) is low compared to the top 25% of dividend payers in the JP market (3.33%).


Stability and Growth of Payments

Stable Dividend: 4578's dividend payments have been volatile in the past 10 years.

Growing Dividend: 4578's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (18.4%), 4578's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Tatsuo Higuchi (71 yo)

no data

Tenure

JP¥244,000,000

Compensation

Mr. Tatsuo Higuchi has been the President and Executive Director of Otsuka Holdings Co., Ltd. since July 2008 and serves as its Chief Executive Officer. Mr. Higuchi has been the President of Otsuka Pharmac...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Tatsuo's total compensation is reasonable compared to companies of similar size in the JP market.

Compensation vs Earnings: Tatsuo's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 4578's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: 4578's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Otsuka Holdings Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Otsuka Holdings Co., Ltd.
  • Ticker: 4578
  • Exchange: TSE
  • Founded: 1921
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥2.186t
  • Shares outstanding: 542.40m
  • Website: https://www.otsuka.com

Number of Employees


Location

  • Otsuka Holdings Co., Ltd.
  • 2-9 Kanda-Tsukasamachi
  • Chiyoda-ku
  • Tokyo
  • 101-0048
  • Japan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 09:19
End of Day Share Price2021/11/30 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.